Proteomics Market to Reach $25 Billion by 2024
Reportlinker Review is a series of posts featuring Innovations, Social and Economic Megatrends to understand the World of Tomorrow. Each post is illustrated with statistics for one industry.
Reportlinker’s Proteomics Industry Review in a nutshell
- Proteomics a tool for disease treatment
- New initiatives announced for Cancer Moonshot
- Protein found in cancer cells also found in neurological diseases
How is the Proteomics market ?
The proteomics market will reach $24.8 billion globally by 2024, forecasts Grand View Research.
The global proteomics market is expected to reach over USD 24.8 billion by 2024 according to a new report by Grand View ResearchThe global proteomics market is expected to reach over USD 24.8 billion by 2024 according to a new report by Grand View ResearchThe global proteomics market is expected to reach over USD 24.8 billion by 2024 according to a new report by Grand View Research
Proteomics is the large scale study of proteins focusing on their structures and functions. Proteomic research is used to develop diagnostic services and new drugs for diseases such as cancer, obesity and diabetes. These diseases are often difficult to treat because body response varies by individual.
The largest product segment is reagents, used to search for cancer biomarkers. It is forecasted to grow at a compound annual growth rate (CAGR) of 8.5%.
The largest segment overall is protein microarray with a 45% market share.
Globally, the largest region is North America, with a 40% market share. Asia-Pacific is forecasted to grow at the fastest rate, 12%, as chronic diseases increase.
Several new initiatives were announced as part of U.S. Vice President Joe Biden’s Cancer Moonshot.
Many of the initiatives are aimed at sharing research data or improving diagnostic tools.
In addition, the U.S. Department of Defense and Environmental Protection Agency will work to find a link between cancer development and the environment.
Meanwhile, the Genomic, Proteomic Spectrometry Cancer test, or GPS Cancer, began being offered to cancer patients in July. The test shows which specific therapies will work for a patient’s cancer and body type.
Current forms of testing look at hundreds of genes. GPS Cancer examines 20,000 genes and compares them to normal DNA. It also examines cell proteins.
Test results will be used to develop a cancer vaccine.
A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and published in Developmental Cell found that amyloid bodies activate cancer cells as they disintegrate. Amyloids also play a role in neurological diseases such as Parkinson’s disease and Alzheimer’s.
Researcher hope to use knowledge gained while studying neurological diseases to treat tumors.
The study also found that RNA controls amyloid formation.
“We may also be able to turn active cancer cells into dormant ones by encouraging them to store the proteins as amyloid bodies,” Stephen Lee, director of the Tumor Biology Program at Sylvester, professor of biochemistry and molecular biology at the Miller School, told Medical Xpress.
ReportLinker Review – Global Proteomics Market
- Over the period 2014-2019, the market is forecasted to grow at a CAGR of 8.4 percent. (source: TechNavio)
- In 2014, the market was valued at $5.1 billion. By 2019, the market is forecasted to reach $11.6 billion, growing at a CAGR of 18%. (source: BCC Research)
- Over the period 2013-2018, the genomics and proteomics analytical instruments market is forecasted to grow at a CAGR of 7.8%. (source: TechNavio)
- In 2015, the market for single-cell analysis products among research, drug development and applied end users was valued at $386.1 million. In 2020, the market is expected to reach $808.5 million, growing at a CAGR of 15.9%. (source: BCC Research)